Cargando…
Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report
Baricitinib is a Janus kinase (JAK) inhibitor used to treat refractory rheumatoid arthritis and blocks the subtypes JAK1 and JAK2. A 35-year-old man with seronegative rheumatoid arthritis complicated by bilateral severe non-granulomatous panuveitis was resistant to steroid treatment, multiple conven...
Autores principales: | Kaneko, Yutaka, Murakami, Takanori, Nishitsuka, Koichi, Takakubo, Yuya, Takagi, Michiaki, Yamashita, Hidetoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795080/ https://www.ncbi.nlm.nih.gov/pubmed/35096866 http://dx.doi.org/10.3389/fmed.2021.764067 |
Ejemplares similares
-
Are There Any Ethnic Differences in the Response to Baricitinib for the Treatment of Rheumatoid Arthritis?
por: Zahir Hussain, Wajith Hussain, et al.
Publicado: (2021) -
Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020) -
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
por: Genovese, Mark C, et al.
Publicado: (2018) -
Progression of Bone and Joint Destruction During the Perinatal Period in Patients With Rheumatoid Arthritis and Juvenile Idiopathic Arthritis in the Last Decade
por: Nagase, Takaaki, et al.
Publicado: (2022) -
Quantification of the peripheral vitreous after vitreous shaving using intraoperative optical coherence tomography
por: Nishitsuka, Koichi, et al.
Publicado: (2021)